aonc-20240521

0001839998-24-000045.txt : 20240521 0001839998-24-000045.hdr.sgml : 20240521 20240521060024 ACCESSION NUMBER: 0001839998-24-000045 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240521 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240521 DATE AS OF CHANGE: 20240521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: American Oncology Network, Inc. CENTRAL INDEX KEY: 0001839998 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40177 FILM NUMBER: 24966744 BUSINESS ADDRESS: STREET 1: 14543 GLOBAL PKWY #110 CITY: FORT MYERS STATE: FL ZIP: 33913 BUSINESS PHONE: 833-886-1725 MAIL ADDRESS: STREET 1: 14543 GLOBAL PKWY #110 CITY: FORT MYERS STATE: FL ZIP: 33913 FORMER COMPANY: FORMER CONFORMED NAME: Digital Transformation Opportunities Corp. DATE OF NAME CHANGE: 20210111 8-K 1 aonc-20240521.htm 8-K aonc-20240521

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 21, 2024

American Oncology Network, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-40177

85-3984427

(State or other jurisdiction of
incorporation or organization)

(Commission File Number)

(I.R.S. Employer
Identification Number)


14543 Global Parkway, Suite 110 Fort Myers, FL									33913
(Address of principal executive offices)									(Zip Code)

(833) 886-1725

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class

Trading

Symbol(s)

Name of each exchange on

which registered

Class A common stock, par value $0.0001, per share

AONC

The Nasdaq Stock Market LLC

Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share

AONCW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On May 21, 2024, American Oncology Network, Inc. (the “Company”) announced that it has determined to voluntarily delist its Class A Common Stock (“Common Stock”) and publicly traded warrants to purchase Class A Common Stock (the “Warrants”) from the Nasdaq Capital Market (“Nasdaq”), as recommended to the Board of Directors (the “Board”) of the Company by a special committee (the “Special Committee”) of the Board comprised solely of disinterested directors. On May 21, 2024, the Company notified Nasdaq of its determination.

In making its determination, the Special Committee concluded that delisting the Company’s securities from Nasdaq is in the best interests of the Company and its stockholders. The Special Committee’s recommendation and the Board’s decision were the product of careful review and consideration of a number of factors, including, but not limited to, (1) the lack of research coverage of the Company by securities and industry analysts, (2) the lack of an active trading market for our securities on Nasdaq, and (3) the required personnel resources and the high costs relating to continued Exchange Act and Nasdaq disclosure and reporting requirements and related regulatory burdens, which have resulted and would continue to result in significant operating expense and significant attention of the Company’s management team. In addition, the Company and certain of its significant equityholders also agreed to certain protections for the holders of the Company’s common equity following the delisting, including (1) in the event such significant equityholders arrange for purchases or other acquisitions of the Company’s outstanding equity securities, such acquisitions would be made at a premium to the trading price of the Company’s Class A common stock prior to delisting, which premium shall not be less than a specified threshold (unless otherwise approved by the Special Committee) and (2) for such equityholders to enter into a customary stockholders’ agreement with the Company under certain circumstances. The Company provides no assurances as to the timing, pricing, or occurrence of any purchases or other acquisitions of the Company’s outstanding equity securities in the future.

A copy of the press release is filed with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.


Exhibit No.						Description
99.1						Press Release of the Company , dated May 21 , 2024
104						Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			AMERICAN ONCOLOGY NETWORK, INC.

			By:			/s/ Todd Schonherz
			Name:			Todd Schonherz
			Title:			Chief Executive Officer
			Dated:			May 21, 2024

EX-99.1 2 aoncdelistingpressrelease.htm EX-99.1 Document

American Oncology Network Announces Voluntary Delisting From Nasdaq

FORT MYERS, Fla. – May 21, 2024 – American Oncology Network (“AON” or the “Company”) (Nasdaq: AONC), a rapidly growing network of community-based oncology practices, announced today its decision to voluntarily delist its Class A common stock and warrants from The Nasdaq Capital Market ("Nasdaq"). The Company’s decision to delist its securities from Nasdaq was recommended to the Board of Directors (the "Board") of the Company by a Special Committee (the "Special Committee") of the Board comprised solely of independent directors.

The Company intends to file a Form 25 with the Securities and Exchange Commission (the “SEC”) to delist its Class A common stock and warrants from Nasdaq and to deregister its Class A common stock and warrants under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), on or about May 31, 2024, and as a result, the Company expects that the last trading day of its Class A common stock and warrants on Nasdaq will be on or about June 7, 2024.

In making its determination, the Special Committee concluded that delisting the Company’s securities from Nasdaq is in the best interests of the Company and its stakeholders. The Special Committee’s recommendation and the Board’s decision were the product of careful review and consideration of a number of factors, including, but not limited to, (1) the lack of research coverage of the Company by securities and industry analysts, (2) the lack of an active trading market for its securities on Nasdaq, and (3) the required personnel resources and expenses relating to continued Exchange Act and Nasdaq disclosure and reporting requirements and related regulatory burdens, which have resulted and would continue to result in significant operating expense and attention of the Company’s management team.

Todd Schonherz, Chief Executive Officer, commented, “AON has delivered an impressive five-year revenue CAGR of 42% and continues to experience strong momentum with the addition of 40 providers and four new practices to the network year-to-date. AON is in a healthy financial position with a robust balance sheet of over $100 million in cash and short-term securities as of March 31, 2024. While going public allowed us to raise growth capital and provide equity to key stakeholders, we believe that we will be better positioned to maximize shareholder value going forward by delisting.”

Following the delisting of the Company’s common stock and warrants from Nasdaq, the Company expects that its common stock and warrants will be quoted for trading on a market operated by OTC Markets Group Inc. (the “OTC”) so that a trading market may continue to exist for such securities. There is no guarantee, however, that a broker will continue to make a market in the common stock and warrants.

About American Oncology Network

American Oncology Network (AON) (Nasdaq: AONC) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 240 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need

to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. Learn more at www.AONcology.com.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company's strategy, intentions to voluntarily delist its securities from Nasdaq and any anticipated results of such actions. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on current expectations as of the date of this press release and involve a number of risks and uncertainties, which may cause results to differ materially from those indicated by these forward-looking statements. Many important factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, but not limited to, future liquidity of the Company's securities, the Company’s continued growth, changes in the Company's board of directors and executive management, and the Company's dependence on its executive management team. The foregoing list of factors is not exhaustive.

You should carefully consider the foregoing factors and the other risks and uncertainties described under the caption "Risk Factors" in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 28, 2024, as amended on April 29, 2024, and the Company's other filings with the SEC. These SEC filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

Investor Contact:
Solebury Strategic Communications
Investors@AONcology.com

EX-101.SCH 3 aonc-20240521.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 aonc-20240521_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 aonc-20240521_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Period End Date Document Period End Date Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Central Index Key Entity Central Index Key Equity Components [Axis] Equity Components [Axis] Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Document Information [Line Items] Document Information [Line Items] Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Warrant Warrant [Member] Document Type Document Type Amendment Flag Amendment Flag Document Information [Table] Document Information [Table] Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 6 aonc-20240521_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	May 21, 2024
Document Information [Line Items]
Document Type	8-K
Document Period End Date	May 21, 2024
Entity Registrant Name	American Oncology Network, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-40177
Entity Tax Identification Number	85-3984427
Entity Address, Address Line One	14543 Global Parkway
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	Fort Myers
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33913
City Area Code	833
Local Phone Number	886-1725
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Central Index Key	0001839998
Amendment Flag	false
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Class A common stock, par value $0.0001, per share
Trading Symbol	AONC
Security Exchange Name	NASDAQ
Warrant
Document Information [Line Items]
Title of 12(b) Security	Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share
Trading Symbol	AONCW
Security Exchange Name	NASDAQ

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 3 23 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.aoncology.com/role/Cover Cover Cover 1 false false All Reports Book All Reports aonc-20240521.htm aonc-20240521.xsd aonc-20240521_def.xml aonc-20240521_lab.xml aonc-20240521_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "aonc-20240521.htm": { "nsprefix": "aonc", "nsuri": "http://www.aoncology.com/20240521", "dts": { "inline": { "local": [ "aonc-20240521.htm" ] }, "schema": { "local": [ "aonc-20240521.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "aonc-20240521_def.xml" ] }, "labelLink": { "local": [ "aonc-20240521_lab.xml" ] }, "presentationLink": { "local": [ "aonc-20240521_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://www.aoncology.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240521.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240521.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant", "label": "Warrant [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001839998-24-000045-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001839998-24-000045-xbrl.zip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end XML 18 aonc-20240521_htm.xml IDEA: XBRL DOCUMENT 0001839998 2024-05-21 2024-05-21 0001839998 us-gaap:CommonStockMember 2024-05-21 2024-05-21 0001839998 us-gaap:WarrantMember 2024-05-21 2024-05-21 0001839998 false 8-K 2024-05-21 American Oncology Network, Inc. DE 001-40177 85-3984427 14543 Global Parkway Suite 110 Fort Myers FL 33913 833 886-1725 false false false false Class A common stock, par value $0.0001, per share AONC NASDAQ Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share AONCW NASDAQ false